drugset / Trial / NCT04526782
ENCOrafenib With Binimetinib in bRAF NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
Timeline
- Start
- 2021-01-19
- Primary completion
- 2025-07-16
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | 45 mg | — |
| Subject | Encorafenib | Small molecule | 450 mg | — |